期刊文献+

外泌体在消化系统肿瘤中的研究进展 被引量:2

Progress in exosomes in human gastrointestinal tumor
原文传递
导出
摘要 外泌体是一种由多种活细胞分泌到细胞外直径为40-100 nm的囊泡小体,其内容物含蛋白质、脂质和核酸等。消化系统肿瘤是人类常见的恶性肿瘤之一,其中胃癌、胰腺癌和结直肠癌等的发病率和死亡率较高。外泌体作为肿瘤学研究的热点,其在消化系统肿瘤发生、发展、临床诊断和治疗方面具有重要的研究价值。本文对外泌体的生物合成、组成成分及其在消化系统肿瘤中的研究进展进行综述。 Exosomes are small vesicular bodies of 40-100 nm secreted by various types of living cells into the extracellular environment,and contain proteins,lipids and nucleic acids.Gastrointestinal tumor is one of the most common malignant tumor.The morbidity and mortality of gastric cancer,pancreatic cancer and colorectal cancer are high among malignant tumors.As a hotspot in the research of oncology,exosomes have potential values in the research of development,diagnosis and treatment of human gastrointestinal tumor.This review summarizes the biogenesis and components of exosomes as well as the progression of exosomes in human gastrointestinal tumor.
出处 《肿瘤》 CAS CSCD 北大核心 2015年第7期810-815,共6页 Tumor
关键词 消化系统肿瘤 生物合成途径 诊断 治疗 外泌体 Digestive system neoplasms Biosynthetic pathways Diagnosis Therapy Exosomes
  • 相关文献

参考文献2

二级参考文献16

  • 1ROTH A D, FAZIO N, STUPP R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase ii trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2007, 25(22): 3217-3223.
  • 2PARK S H, LEE W K, CHUNG M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: A randomized phase Ⅱ trial in combination with infusional 5-fluorouracil[J]. Anticancer Drugs, 2006, 17(2): 225-229.
  • 3BOKU N, YAMAMOTO S, FUKUDA H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study[J]. Lancet Oncol, 2009, 10(11 ): 1063-1069.
  • 4MOCHIKI E, OHNO T, KAMIYAMA Y, et al. Phase I / Ⅱ study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer[J]. Br J Cancer, 2006, 95(12): 1642-1647.
  • 5INADA S, TOMIDOKORO T, FUKUNARI H, etal. Phase I / Ⅱ trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer[J]. Cancer Chemother Pharmacol, 2009, 63(2): 267-273.
  • 6KAWABATA R, FUJIWARA Y, DOKI Y, et al. Phase I / Ⅱ study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer[J]. Oncology, 2007, 72(3-4): 219-225.
  • 7UEDA Y, YAMAGISHI H, ICHIKAWA D, et al. Multicenter phase Ⅱ study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer[J]. Gastric Cancer, 2010, 13(3): 149-154.
  • 8O'DWYER P J, LACRETA F, HOGAN M, et al. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route[J]. J Clin Pharmacol, 1991, 31(3): 253-258.
  • 9FUJIWARA Y, TAKIGUCHI S, NAKAJIMA K, et al Intraperitoneal docetaxel combined with s-1 for advanced gastric cancer with peritonea dissemination[J].J Surg Oncol, 2012, 105(1) 38-42.
  • 10ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. NEnglJMed, 2006, 354(1): 34-43.

共引文献41

同被引文献18

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部